At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 25 enrolled
Drug / intervention
NOX66 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NOX66 and Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer - a Phase 1b Proof of Concept and Dose Confirmation Study
In Brief
A Phase 1 clinical trial evaluating NOX66 and Irradiation Therapy for Cancer. Completed, enrolled 25 participants across 10 sites in 3 countries.
Detailed Summary
The study is intended as a Proof of Concept and dose confirmation study. The primary objective of this study is to observe safety and tolerability of idronoxil (NOX66) in combination with radiotherapy (at palliative doses) in patients with metastatic castrate-resistant prostate cancer (CRPC) and to confirm dose in order to progress to Phase 2/3.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesAustralia, Georgia, New Zealand
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartNov 2017
Primary CompletionDec 2019
Study CompletionSep 2020
TodayJul 2026
First PostedOct 12, 2017
Enrollment StartNov 1, 2017
Primary CompletionDec 1, 2019
Study CompletionSep 15, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.7 years ago
Interventions
NOX66drug
NOX66 delivered as rectal suppository.
Irradiation Therapyradiation
Radiation per selected tumour lesion.